Condition (MeSH)
Glucagonoma
ClinicalTrials.gov lists 33 trials for Glucagonoma or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 8.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
33 of the 33 trials are tagged with Glucagonoma itself; the rest are tagged with a narrower condition beneath it.
When did Glucagonoma trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 2
- Phase 2/3
- Phase 3
- Not applicable
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2018 | 2 |
| 2017 | 1 |
| 2016 | 1 |
| 2014 | 3 |
| 2013 | 1 |
| 2012 | 1 |
| 2010 | 2 |
| 2009 | 1 |
| 2008 | 1 |
| 2007 | 2 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 33 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Glucagonoma trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 19 |
| Phase 2/3 | 1 |
| Phase 3 | 1 |
| Not applicable | 1 |
| Observational | 2 |
How many Glucagonoma trials are recruiting? (5)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Active, not recruiting | 1 |
| Completed | 20 |
| Terminated | 8 |
| Withdrawn | 3 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Glucagonoma trials? (6)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 8 |
| ECOG-ACRIN Cancer Research Group | 2 |
| Eastern Cooperative Oncology Group | 2 |
| Delcath Systems Inc. | 1 |
| INSYS Therapeutics Inc | 1 |
Showing 5 of 6 sponsors.
Which drugs are being tested for Glucagonoma? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| "Capecitabine" | 4 |
| EVEROLIMUS | 4 |
| Calcium Leucovorin | 3 |
| OXALIPLATIN | 2 |
| Vatalanib | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| LAR Octreotide | 4 |
| SOC: Temozolomide | 3 |
| Fluorouracile | 2 |
| Bortezomib SC | 2 |
| Bevacizumab 1 | 2 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Glucagonoma trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Abdominal pain | 29 | 5 |
| Fatigue | 29 | 4 |
| Nausea | 25 | 5 |
| Vomiting | 20 | 5 |
| Diarrhea | 17 | 5 |
Showing 5 of 10 adverse events.
Which publications cover Glucagonoma? (3)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Induction of intestinal epithelial proliferation by glucagon-like peptide 2. | Proceedings of the National Academy of Sciences of the United States of America | 1996 | Yes |
| Timing and extent of surgery in symptomatic and asymptomatic neuroendocrine tumors of the pancreas in MEN 1. | Langenbeck's archives of surgery | 2002 | No |
| Interleukin-6 mediates host defense responses induced by abdominal surgery. | Surgery | 1993 | No |
Prevalence (6)
Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.
| Orphanet disease | Type | Class | Geography | Jurisdiction | Mapping relation |
|---|---|---|---|---|---|
| Glucagonoma | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Glucagonoma | Point prevalence | <1 / 1 000 000 | Europe | Not stated | Unspecified |
| Glucagonoma | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Glucagonoma | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Exact |
| Glucagonoma | Annual incidence | <1 / 1 000 000 | Europe | Not stated | Unspecified |
Showing 5 of 6 prevalence observations.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Glucagonoma | 97280 | Exact | Orphadata Science knowledge files, Product 1 |
| Glucagonoma | 97280 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: sub-conditions in mesh.